Status:
RECRUITING
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
Lead Sponsor:
Washington State University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Neonatal Abstinence Syndrome
Opioid-use Disorder
Eligibility:
FEMALE
18-99 years
Phase:
NA
Brief Summary
Most newborns experiencing Neonatal Abstinence Syndrome (NAS) require non-pharmacologic care, which entails, most importantly, maternal involvement with her newborn. To facilitate positive maternal-ne...
Detailed Description
Due to an alarming rise in opioid use among the general population that is mirrored in pregnant women, Neonatal Abstinence Syndrome (NAS) rates have increased in the US from 2004 to 2014. Most newborn...
Eligibility Criteria
Inclusion
- Pregnant woman in the third trimester currently in OAT treatment for opioid use disorder
- 18 years of age or older
- Ability to speak and understand English.
Exclusion
- • Recurring (e.g. daily or almost daily) thoughts of harming themselves or others in the past 2 weeks.
Key Trial Info
Start Date :
July 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04783558
Start Date
July 15 2024
End Date
June 30 2025
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington State University
Spokane, Washington, United States, 99210